HOME >> MEDICINE >> NEWS
Survival benefit for rheumatoid arthritis patients treated with methotrexate

The anticancer drug methotrexate could have a substantial survival benefit among patients with rheumatoid arthritis, conclude authors of a prospective US study in this weeks issue of THE LANCET.

Rheumatoid arthritis is a chronic inflammatory disease which results in reduced life-expectancy and is associated with cardiovascular disease, infection, and cancer. Low-dose methotrexate is the main choice of antirheumatic therapy for rheumatoid arthritis, although its effect on mortality for patients with the disease is not known.

Hyon Choi from Harvard Medical School and Harvard School of Public Health, Frederick Wolfe from University of Kansas School of Medicine, USA, and colleagues prospectively studied 1240 patients with rheumatoid arthritis over the past two decades. 191 individuals died during follow-up. Patients who began treatment with methotrexate (around half of the study population) had more severe rheumatoid arthritis. After adjustment for this confounding factor, methotrexate was found to have a 60% survival benefit for all-cause mortality compared with those who did not use methotrexate, and a 70% survival benefit for cardiovascular death.

Hyon Choi comments: Our data indicate that methotrexate may provide a substantial survival benefit, largely by reducing cardiovascular mortality. This gain in life expectancy could be considered in selecting a cost-effective, disease-modifying antirheumatic drug on a long-term basis. Additionally, the survival benefit of methotrexate would set a standard against which new disease-modifying antirheumatic drugs should be compared.


'"/>

Contact: Richard Lane
richard.lane@lancet.com
44-0-20-7424-4949
Lancet
4-Apr-2002


Page: 1

Related medicine news :

1. Survival sex and substance abuse may hinder HIV prevention efforts
2. Survival improves in clinical trial for severe birth defect, with or without fetal surgery
3. Abgenix Reports Positive Survival Data From A Phase II Trial Of ABX-CBL In Graft Versus Host Disease
4. American Heart Association Comment: Contributions Of Trends In Survival And Coronary-Event Rates To Changes In Coronary Heart Disease Mortality
5. Early Heart Repair For Marfan Syndrome Patients Critical To Survival
6. Intensive Care Before A Major Op May Improve Survival
7. Sex And Survival: In Some Matters Of The Heart Women Have The Edge
8. Study: Birth Defects Decrease Survival, Childbirth, Boost Risk Of Similar Defects
9. Study Indicates That Medicare Costs Are Higher -- And Survival Rate Is Better --At Major Teaching Hospitals Survive Climate Change
10. Maxim Phase II Clinical Trial Highlights Substantial Increase In Leukemia-FreeSurvival For Acute Myelogenous Leukemia Patients
11. Beta Blocker Significantly Improves Heart Failure Survival

Post Your Comments:
(Date:3/28/2015)... With more than 4,500 scientists, clinicians ... osteoarthritis and musculoskeletal diseases gathered here for the ... first time in the 17-year history of the ... topic is an emerging non-pharmaceutical protocol for enhancing ... of Wolff’s law, osteogenic loading at multiples of ...
(Date:3/28/2015)... (PRWEB) March 28, 2015 Emergency Medical ... urgent care in Manhattan, recently commemorated its three-year anniversary ... in Manhattan. In addition to 24-hour urgent care, Emergency ... , At this time, Emergency Medical Care’s ... pain, asthma, chest pain, eye injuries, ear infections, fevers, ...
(Date:3/28/2015)... 28, 2015 Centurion Service Group will be ... Thursday, April 2 at their Las Vegas warehouse, located at ... The sale, which consists of equipment from hospitals and surgery ... 9 a.m. PDT. , Buyers will find items of ... “We are a one-stop-shop,” said Erik Tivin, CEO of Centurion. ...
(Date:3/28/2015)... 2015 How best to treat and ... in orthopaedic medicine. While diagnostic hip injections are commonly ... pain etiology, research presented today at the American Orthopaedic ... suggests that pain relief from this diagnostic injection may ... , “Our study looked to assess if the amount ...
(Date:3/28/2015)... 28, 2015 Genomic medicine experts have ... revealing, for the first time, key information for understanding ... read the newly posted story on the Surviving ... of British Columbia, the British Columbia Cancer Agency, and ... reveal underlying molecular alterations and mutations that can lead ...
Breaking Medicine News(10 mins):Health News:Non-Drug Protocol for Building Bone Density Expected to Steal Spotlight at World Congress on Osteoporosis 2Health News:Emergency Medical Care Celebrates Three Years of 24/7 Walk-In Urgent Care Services 2Health News:Medical Equipment Auction to Take Place in North Las Vegas 2Health News:Pain Injections for Hip Arthroscopy Patients May Not Predict Surgical Outcomes 2Health News:New Genomics Research May Help Doctors Tailor Mesothelioma Treatment, According to Surviving Mesothelioma 2
(Date:3/27/2015)... , March 27, 2015 Levi & Korsinsky ... Inc. (NASDAQ: OHRP ) concerning possible violations of ... by the Company in connection with its study of ... http://zlk.9nl.com/ohr-pharmaceutical-ohrp or contact Joseph E. Levi, ... or by telephone at (212) 363-7500, toll-free: (877) 363-5972. ...
(Date:3/27/2015)... - Medicure Inc. (the "Company") (TSXV:MPH, OTCQB:MCUJF) announces today ... of an aggregate of 236,070 options to certain directors, ... Company pursuant to the Company,s Stock Option Plan. Of ... tenth anniversary of the date of grant, 5,000 are ... date of grant and 50,000 are set to expire ...
(Date:3/27/2015)... 27, 2015 /CNW Telbec/ - Russell Williams , ... Companies (Rx&D), welcomes the 2015-2016 Quebec Budget, noting the ... on the biopharmaceutical industry. However, the association is concerned ... "We commend the government,s intent to strive for a ... to promote Quebec,s economic development ...
Breaking Medicine Technology:Quebec 2015-2016 Budget: Rx&D welcomes fiscal discipline and biopharma working group, but the decrease in government spending on medicines is questioned 2Quebec 2015-2016 Budget: Rx&D welcomes fiscal discipline and biopharma working group, but the decrease in government spending on medicines is questioned 3
Cached News: